Mei Pharma Inc Cmn (MEIP) 1.76 $MEIP MEI Pharma
Post# of 273257
Posted On: 09/03/2016 7:19:00 AM
Mei Pharma Inc Cmn (MEIP) 1.76 $MEIP
MEI Pharma to Present at Wedbush PacGrow Healthcare Conference
PR Newswire - Wed Aug 10, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 8:00 a.m. Eastern time from Le Parker Meridien in New York. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)
Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialization of Pracinostat for the Treatment of Acute Myeloid Leukemia and Other Hematologic Diseases
PR Newswire - Mon Aug 08, 7:00AM CDT
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that they have entered into an exclusive licensing, development and commercialization agreement for Pracinostat, a Phase III-ready drug candidate for the treatment of acute myeloid leukemia (AML) and other potential indications. The deal provides the complementary resources from both organizations to rapidly advance Pracinostat into Phase III clinical development and expand into additional indications, including high-risk myelodysplastic syndrome (MDS).
MEIP: 1.76 (+0.02)
MEI Pharma's Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
PR Newswire - Mon Aug 01, 7:30AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational drug Pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are greater-than or equal to 75 years of age or unfit for intensive chemotherapy. In addition, agreement has been reached with the FDA on the Company's proposed Phase III study design.
MEIP: 1.76 (+0.02)
MEI Pharma Announces New Clinical Data from First-in-Human Study of ME-401, A Next Generation Oral PI3K Delta Inhibitor
PR Newswire - Wed Apr 20, 7:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced new clinical data from a first-in-human study of MEI Pharma's investigational drug candidate, ME-401, a next generation oral PI3K delta inhibitor. The data, presented today at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, suggest that ME-401 has an excellent pharmacokinetic (PK) and pharmacodynamic (PD) profile and the potential for an improved therapeutic window compared to other PI3K delta inhibitors, including the approved drug idelalisib (marketed as Zydelig®), with a half-life that supports once-daily dosing.
MEIP: 1.76 (+0.02)
MEI Pharma (MEIP) in Focus: Stock Rises 7.9% in Session
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:35AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares climb nearly 8% on the day.
ADHD: 4.77 (+0.03), MEIP: 1.76 (+0.02)
MEI Pharma to Present at Needham Healthcare Conference
PR Newswire - Tue Apr 05, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:40 p.m. Eastern time from the Westin Grand Central Hotel in New York. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)
MEI Pharma to Present at BIO CEO & Investor Conference
PR Newswire - Mon Feb 01, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Monday, February 8, 2016 at 4:30 p.m. Eastern time from the Waldorf Astoria New York. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)
World Small-Cell Lung Cancer Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/3zbk4w/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Small-Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Small-Cell Lung Cancer - Overview - Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis - Small-Cell Lung Cancer - Therapeutics under Development by Companies - Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Small-Cell Lung Cancer - Products under Development by Companies - Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Andarix Pharmaceuticals, Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - G1 Therapeutics, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Karyopharm Therapeutics, Inc. - Kolltan Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - MEI Pharma, Inc. - Merck & Co., Inc. - NanoSmart Pharmaceuticals, Inc. - Nippon Kayaku Co., Ltd. - Novartis AG - Pfizer Inc. - Polaris Pharmaceuticals, Inc. - Rexahn Pharmaceuticals, Inc. - Spectrum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3z...lcell_lung
RNN: 0.26 (+0.01), MBVX: 5.09 (+0.11), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), SPPI: 5.24 (-0.05), BIND: 0.78 (-0.09), LLY: 76.85 (-0.38), BMY: 56.35 (-0.41), GSK: 44.26 (+1.28), MEIP: 1.76 (+0.02), MRK: 62.98 (+0.08), ABBV: 64.12 (+0.09), NVS: 79.38 (+1.11), KPTI: 10.62 (-0.48), ARRY: 3.50 (-0.02), EXEL: 11.54 (+0.19)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
MBVX: 5.09 (+0.11), PCYC: 261.25 (+1.70), AMPE: 0.85 (-0.01), GSK: 44.26 (+1.28), MEIP: 1.76 (+0.02), AAAP: 34.63 (+0.22), MACK: 4.53 (-0.06), PGNX: 5.96 (-0.18), BLCM: 17.24 (-0.23), CYCC: 5.71 (unch), RXDX: 5.90 (+0.02), MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), JUNO: 28.44 (-0.85), CBLI: 1.86 (-0.13), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05)
MEI Pharma elects Christine White, MD as board chair
M2 - Fri Dec 11, 4:16AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) revealed on Thursday that it has appointed Christine White, MD as chairman of the board of directors.
MEIP: 1.76 (+0.02)
MEI Pharma Appoints Dr. Christine White as Chairman of the Board
PR Newswire - Thu Dec 10, 7:30AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Christine White, M.D., as Chairman of the Board of Directors. Dr. White joined the Company's board in August 2010 and has served as its Lead Director since the retirement of former Chairman, Professor Bryan R.G. Williams, Ph.D., in January 2013.
MEIP: 1.76 (+0.02)
MEI Pharma (MEIP) Worth Watching: Stock Gains 5.4%
Zacks Equity Research - Zacks Investment Research - Wed Dec 09, 7:00AM CST
MEI Pharma (MEIP) was a big mover last session, with its shares rising over 5% on the day.
CORT: 5.31 (-0.04), MEIP: 1.76 (+0.02)
Global Brain Cancer Therapeutics Pipeline Review, H2 2015
M2 - Wed Dec 09, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wpxrw/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - AngioChem Inc. - Arrien Pharmaceuticals, LLC - BeiGene(Beijing) Co.,Ltd - Berg, LLC - biOasis Technologies Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC - Diffusion Pharmaceuticals LLC - e-Therapeutics Plc - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - MEI Pharma, Inc. - NatureWise Biotech & Medicals Corporation - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Novogen Limited - Oncology Research International Limited - Oncolytics Biotech Inc. - Oncothyreon Inc. - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Sanofi - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Takeda Pharmaceutical Company Limited - Tocagen Inc. - ViraTherapeutics GmbH - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/2w...ain_cancer
ONCY: 0.33 (-0.02), PFE: 34.77 (+0.09), SPPI: 5.24 (-0.05), BMY: 56.35 (-0.41), STML: 8.03 (-0.12), ONTY: 1.21 (+0.02), NKTR: 18.45 (+0.34), MEIP: 1.76 (+0.02), ATNM: 1.70 (-0.06), ABBV: 64.12 (+0.09), EXEL: 11.54 (+0.19), NVS: 79.38 (+1.11)
MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study
PR Newswire - Mon Dec 07, 7:30AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced positive results from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine (marketed as Vidaza®) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The results were presented earlier today at the American Society of Hematology (ASH) Annual Meeting in Orlando. A copy of the presentation is now available at www.meipharma.com.
MEIP: 1.76 (+0.02)
MEI Pharma to Host Annual Meeting of Stockholders
PR Newswire - Mon Nov 23, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Eastern time on Thursday, December 3, 2015, at the offices of Morgan, Lewis & Bockius LLP, located at 101 Park Avenue, New York, NY 10178. Stockholders of record at the close of business on October 7, 2015 are entitled to receive notice of and vote at the Annual Meeting. A live webcast of the meeting will be accessible at www.meipharma.com. A replay will be available approximately one hour after its conclusion.
MEIP: 1.76 (+0.02)
MEI Pharma to Present at Stifel Healthcare Conference
PR Newswire - Wed Nov 11, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Stifel 2015 Healthcare Conference on Wednesday, November 18, 2015 at 8:00 a.m. Eastern time from the New York Palace Hotel. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)
MEI Pharma Highlights New Data from Phase II Clinical Studies of Pracinostat in Acute Myeloid Leukemia and Myelodysplastic Syndrome
PR Newswire - Thu Nov 05, 8:07AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the publication of new data from the Company's Phase II clinical studies of the investigational drug Pracinostat in patients with previously untreated myelodysplastic syndrome (MDS) and elderly patients with acute myeloid leukemia (AML). Results from these studies were recently selected for oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting in Orlando on December 7, 2015. The abstracts are now available on the ASH website at www.hematology.org.
MEIP: 1.76 (+0.02)
MEI Pharma to Present at 14th Annual BIO Investor Forum
PR Newswire - Mon Oct 19, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that David Urso, JD, Senior Vice President, Corporate Development & General Counsel, will present at the 14th Annual Biotechnology Industry Organization (BIO) Investor Forum on Wednesday, October 21, 2015 at 9:00 a.m. Pacific time from the Parc 55 San Francisco. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)
MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting
PR Newswire - Tue Oct 06, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that data from the Company's Phase II clinical studies of Pracinostat in elderly acute myeloid leukemia (AML) and previously untreated myelodysplastic syndrome (MDS) have been selected by the American Society of Hematology (ASH) Program Committee for oral presentation at the 57th ASH Annual Meeting & Exposition in Orlando on December 7, 2015.
MEIP: 1.76 (+0.02)
Strength Seen in MEI Pharma (MEIP): Stock Jumps 11.1%
Zacks Equity Research - Zacks Investment Research - Thu Aug 20, 8:04AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares rise over 11% on the day.
ADHD: 4.77 (+0.03), MEIP: 1.76 (+0.02)
MEI Pharma to Present at Wedbush PacGrow Healthcare Conference
PR Newswire - Wed Aug 10, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 8:00 a.m. Eastern time from Le Parker Meridien in New York. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)
Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialization of Pracinostat for the Treatment of Acute Myeloid Leukemia and Other Hematologic Diseases
PR Newswire - Mon Aug 08, 7:00AM CDT
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that they have entered into an exclusive licensing, development and commercialization agreement for Pracinostat, a Phase III-ready drug candidate for the treatment of acute myeloid leukemia (AML) and other potential indications. The deal provides the complementary resources from both organizations to rapidly advance Pracinostat into Phase III clinical development and expand into additional indications, including high-risk myelodysplastic syndrome (MDS).
MEIP: 1.76 (+0.02)
MEI Pharma's Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
PR Newswire - Mon Aug 01, 7:30AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational drug Pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are greater-than or equal to 75 years of age or unfit for intensive chemotherapy. In addition, agreement has been reached with the FDA on the Company's proposed Phase III study design.
MEIP: 1.76 (+0.02)
MEI Pharma Announces New Clinical Data from First-in-Human Study of ME-401, A Next Generation Oral PI3K Delta Inhibitor
PR Newswire - Wed Apr 20, 7:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced new clinical data from a first-in-human study of MEI Pharma's investigational drug candidate, ME-401, a next generation oral PI3K delta inhibitor. The data, presented today at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, suggest that ME-401 has an excellent pharmacokinetic (PK) and pharmacodynamic (PD) profile and the potential for an improved therapeutic window compared to other PI3K delta inhibitors, including the approved drug idelalisib (marketed as Zydelig®), with a half-life that supports once-daily dosing.
MEIP: 1.76 (+0.02)
MEI Pharma (MEIP) in Focus: Stock Rises 7.9% in Session
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:35AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares climb nearly 8% on the day.
ADHD: 4.77 (+0.03), MEIP: 1.76 (+0.02)
MEI Pharma to Present at Needham Healthcare Conference
PR Newswire - Tue Apr 05, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:40 p.m. Eastern time from the Westin Grand Central Hotel in New York. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)
MEI Pharma to Present at BIO CEO & Investor Conference
PR Newswire - Mon Feb 01, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Monday, February 8, 2016 at 4:30 p.m. Eastern time from the Waldorf Astoria New York. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)
World Small-Cell Lung Cancer Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/3zbk4w/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Small-Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Small-Cell Lung Cancer - Overview - Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis - Small-Cell Lung Cancer - Therapeutics under Development by Companies - Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Small-Cell Lung Cancer - Products under Development by Companies - Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Andarix Pharmaceuticals, Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - G1 Therapeutics, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Karyopharm Therapeutics, Inc. - Kolltan Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - MEI Pharma, Inc. - Merck & Co., Inc. - NanoSmart Pharmaceuticals, Inc. - Nippon Kayaku Co., Ltd. - Novartis AG - Pfizer Inc. - Polaris Pharmaceuticals, Inc. - Rexahn Pharmaceuticals, Inc. - Spectrum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3z...lcell_lung
RNN: 0.26 (+0.01), MBVX: 5.09 (+0.11), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), SPPI: 5.24 (-0.05), BIND: 0.78 (-0.09), LLY: 76.85 (-0.38), BMY: 56.35 (-0.41), GSK: 44.26 (+1.28), MEIP: 1.76 (+0.02), MRK: 62.98 (+0.08), ABBV: 64.12 (+0.09), NVS: 79.38 (+1.11), KPTI: 10.62 (-0.48), ARRY: 3.50 (-0.02), EXEL: 11.54 (+0.19)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
MBVX: 5.09 (+0.11), PCYC: 261.25 (+1.70), AMPE: 0.85 (-0.01), GSK: 44.26 (+1.28), MEIP: 1.76 (+0.02), AAAP: 34.63 (+0.22), MACK: 4.53 (-0.06), PGNX: 5.96 (-0.18), BLCM: 17.24 (-0.23), CYCC: 5.71 (unch), RXDX: 5.90 (+0.02), MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), JUNO: 28.44 (-0.85), CBLI: 1.86 (-0.13), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05)
MEI Pharma elects Christine White, MD as board chair
M2 - Fri Dec 11, 4:16AM CST
Oncology company MEI Pharma (NasdaqCM:MEIP) revealed on Thursday that it has appointed Christine White, MD as chairman of the board of directors.
MEIP: 1.76 (+0.02)
MEI Pharma Appoints Dr. Christine White as Chairman of the Board
PR Newswire - Thu Dec 10, 7:30AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Christine White, M.D., as Chairman of the Board of Directors. Dr. White joined the Company's board in August 2010 and has served as its Lead Director since the retirement of former Chairman, Professor Bryan R.G. Williams, Ph.D., in January 2013.
MEIP: 1.76 (+0.02)
MEI Pharma (MEIP) Worth Watching: Stock Gains 5.4%
Zacks Equity Research - Zacks Investment Research - Wed Dec 09, 7:00AM CST
MEI Pharma (MEIP) was a big mover last session, with its shares rising over 5% on the day.
CORT: 5.31 (-0.04), MEIP: 1.76 (+0.02)
Global Brain Cancer Therapeutics Pipeline Review, H2 2015
M2 - Wed Dec 09, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wpxrw/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - AngioChem Inc. - Arrien Pharmaceuticals, LLC - BeiGene(Beijing) Co.,Ltd - Berg, LLC - biOasis Technologies Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC - Diffusion Pharmaceuticals LLC - e-Therapeutics Plc - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - MEI Pharma, Inc. - NatureWise Biotech & Medicals Corporation - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Novogen Limited - Oncology Research International Limited - Oncolytics Biotech Inc. - Oncothyreon Inc. - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Sanofi - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Takeda Pharmaceutical Company Limited - Tocagen Inc. - ViraTherapeutics GmbH - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/2w...ain_cancer
ONCY: 0.33 (-0.02), PFE: 34.77 (+0.09), SPPI: 5.24 (-0.05), BMY: 56.35 (-0.41), STML: 8.03 (-0.12), ONTY: 1.21 (+0.02), NKTR: 18.45 (+0.34), MEIP: 1.76 (+0.02), ATNM: 1.70 (-0.06), ABBV: 64.12 (+0.09), EXEL: 11.54 (+0.19), NVS: 79.38 (+1.11)
MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study
PR Newswire - Mon Dec 07, 7:30AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced positive results from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine (marketed as Vidaza®) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The results were presented earlier today at the American Society of Hematology (ASH) Annual Meeting in Orlando. A copy of the presentation is now available at www.meipharma.com.
MEIP: 1.76 (+0.02)
MEI Pharma to Host Annual Meeting of Stockholders
PR Newswire - Mon Nov 23, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Eastern time on Thursday, December 3, 2015, at the offices of Morgan, Lewis & Bockius LLP, located at 101 Park Avenue, New York, NY 10178. Stockholders of record at the close of business on October 7, 2015 are entitled to receive notice of and vote at the Annual Meeting. A live webcast of the meeting will be accessible at www.meipharma.com. A replay will be available approximately one hour after its conclusion.
MEIP: 1.76 (+0.02)
MEI Pharma to Present at Stifel Healthcare Conference
PR Newswire - Wed Nov 11, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Stifel 2015 Healthcare Conference on Wednesday, November 18, 2015 at 8:00 a.m. Eastern time from the New York Palace Hotel. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)
MEI Pharma Highlights New Data from Phase II Clinical Studies of Pracinostat in Acute Myeloid Leukemia and Myelodysplastic Syndrome
PR Newswire - Thu Nov 05, 8:07AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the publication of new data from the Company's Phase II clinical studies of the investigational drug Pracinostat in patients with previously untreated myelodysplastic syndrome (MDS) and elderly patients with acute myeloid leukemia (AML). Results from these studies were recently selected for oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting in Orlando on December 7, 2015. The abstracts are now available on the ASH website at www.hematology.org.
MEIP: 1.76 (+0.02)
MEI Pharma to Present at 14th Annual BIO Investor Forum
PR Newswire - Mon Oct 19, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that David Urso, JD, Senior Vice President, Corporate Development & General Counsel, will present at the 14th Annual Biotechnology Industry Organization (BIO) Investor Forum on Wednesday, October 21, 2015 at 9:00 a.m. Pacific time from the Parc 55 San Francisco. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEIP: 1.76 (+0.02)
MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting
PR Newswire - Tue Oct 06, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that data from the Company's Phase II clinical studies of Pracinostat in elderly acute myeloid leukemia (AML) and previously untreated myelodysplastic syndrome (MDS) have been selected by the American Society of Hematology (ASH) Program Committee for oral presentation at the 57th ASH Annual Meeting & Exposition in Orlando on December 7, 2015.
MEIP: 1.76 (+0.02)
Strength Seen in MEI Pharma (MEIP): Stock Jumps 11.1%
Zacks Equity Research - Zacks Investment Research - Thu Aug 20, 8:04AM CDT
MEI Pharma, Inc. (MEIP) was a big mover last session, as the company saw its shares rise over 11% on the day.
ADHD: 4.77 (+0.03), MEIP: 1.76 (+0.02)
(0)
(0)Scroll down for more posts ▼